Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Agenus is an immuno-oncology company designed to deliver innovation with speed for...
Agenus is an immuno-oncology company designed t...
Cytonics, founded in 2006, is a private research and development company focused o...
Cytonics, founded in 2006, is a private researc...
Landec Corporation (Nasdaq: LNDC) is a leading innovator of diversified health and...
Landec Corporation (Nasdaq: LNDC) is a leading ...
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
Mustang Bio, Inc. (âMustangâ), a Fortress Biotech Company, is a clinical-stage...
Mustang Bio, Inc. (âMustangâ), a Fortress B...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Diffusion Pharmaceuticals is a clinical stage company focused on improving the eff...
Diffusion Pharmaceuticals is a clinical stage c...
Join the National Investor Network and get the latest information with your interests in mind.